Business Context and Reporting Period
The filing is Aileron Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2024; the provided metadata identifies Rein Therapeutics, Inc., which does not match the registrant named in the filing. Aileron is a clinical-stage biopharmaceutical company developing therapies for orphan pulmonary and fibrosis indications. Following its October 2023 acquisition of Lung Therapeutics, its principal candidates are LTI-03 for idiopathic pulmonary fibrosis and LTI-01 for loculated pleural effusion, with additional preclinical programs.
The company has no approved products, has generated no product revenue, and has never generated an operating profit. Its common stock trades on Nasdaq under the symbol ALRN.
Financial Performance and Position
| Metric | Three months ended March 31, 2024 | Three months ended March 31, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.463 million | $1.810 million |
| General and administrative expense | $3.742 million | $2.179 million |
| Restructuring and other costs | $0 | $1.022 million |
| Total operating expenses | $7.205 million | $5.011 million |
| Loss from operations | $7.205 million | $5.011 million |
| Other income, net | $0.092 million | $0.232 million |
| Net loss | $7.113 million | $4.779 million |
| Basic and diluted loss per share | $0.86 loss | $1.05 loss |
| Net cash used in operating activities | $5.271 million | $4.661 million |
At March 31, 2024, cash and cash equivalents were $12.042 million, compared with $17.313 million at December 31, 2023. Including restricted cash, total cash, cash equivalents and restricted cash were $12.067 million. Total assets were $99.192 million, including $79.200 million of indefinite-lived intangible assets and $6.330 million of goodwill from the Lung acquisition. Total liabilities were $7.858 million, and accumulated deficit was $295.630 million.
The filing reports no debt outstanding. Current liabilities were $4.532 million, consisting primarily of accounts payable and accrued expenses. The company had $2.339 million of non-cancellable contract manufacturing purchase obligations, with $0 due in 2024 and $2.339 million due in 2025 and thereafter.
Operating cash usage increased primarily because of the higher net loss and expanded clinical, manufacturing and corporate activities. There were no investing or financing cash flows during the quarter; the prior-year investing inflow of $7.250 million reflected sales or maturities of investments.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased $1.653 million, or approximately 91%, primarily due to activities acquired through the Lung transaction. The 2024 period included approximately $1.1 million for clinical trials, $1.6 million for manufacturing, $0.2 million for regulatory and development consulting, and $0.6 million for employee-related clinical program costs.
- General and administrative expense increased $1.563 million, or approximately 72%, driven by higher professional fees, employee-related costs, facilities and other expenses following the Lung acquisition.
- Restructuring expense decreased $1.022 million because the workforce reduction charges recorded in the 2023 period were completed and no comparable costs were incurred in 2024.
- Net loss increased $2.334 million, or approximately 49%, to $7.113 million.
- Weighted-average common shares increased to 8.302 million from 4.541 million, primarily reflecting conversions of Series X preferred stock.
- On March 5, 2024, 11,957 shares of Series X preferred stock automatically converted into 11.957 million common shares. At March 31, 2024, 12,653 preferred shares remained outstanding and were convertible into 12.653 million common shares, subject to beneficial ownership limitations.
- The company’s Austin office lease expired on March 31, 2024, and management expects to operate virtually for the foreseeable future.
Guidance, Outlook, Risks and Unusual Items
Management expects continued operating losses and significant spending as it advances LTI-03 and LTI-01. It states that cash and cash equivalents, including proceeds from a subsequent offering, are expected to fund operations into the second half of 2025, based on the current operating plan. Management cautions that actual cash usage could be faster and that additional capital may be required.
On May 1, 2024, the company entered into an underwritten offering that closed May 3, 2024, issuing 4,273,505 common shares and warrants to purchase an additional 4,273,505 shares. Net proceeds were approximately $17.945 million, excluding potential warrant exercise proceeds. The offering warrants have a $4.68 exercise price and generally expire three years after issuance. The company reported cash and cash equivalents of approximately $27.496 million as of May 3, 2024, after the offering.
Management announced positive Cohort 1 data from the ongoing Phase 1b LTI-03 trial on May 1, 2024. Twelve patients were enrolled, with nine receiving LTI-03 and three receiving placebo. The company reported positive trends in seven of eight biomarkers, statistically significant results for three biomarkers, no serious adverse events, and general tolerability. Higher-dose Cohort 2 topline results were expected in the third quarter of 2024. The filing cautions that Cohort 1 results may not predict the full trial outcome.
- The company remains dependent on clinical and regulatory success, patient enrollment, third-party manufacturers and additional financing.
- There is substantial dilution risk from the preferred stock conversions, outstanding options, warrants and the May 2024 offering.
- Management concluded that disclosure controls and procedures were not effective as of March 31, 2024 because of material weaknesses in internal control over financial reporting, including weaknesses related to the Lung acquisition, segregation of duties, account-reconciliation reviews and timely financial reporting.
- Remediation efforts are ongoing, but the weaknesses will not be considered remediated until controls operate effectively for a sufficient period and are successfully tested.
- The filing reports no material pending legal proceedings and no material impairment of goodwill or indefinite-lived intangible assets as of March 31, 2024.
- The company relies on a limited number of third-party manufacturers and has license obligations that may include milestone payments, royalties, sublicense fees and patent-related costs.
Investor Verification Items
- Verify the registrant identity: the filing names Aileron Therapeutics, Inc., while the request metadata names Rein Therapeutics, Inc.
- Confirm the May 2024 financing terms, net proceeds, warrant coverage, exercise price and resulting fully diluted share count.
- Assess whether the stated cash runway into the second half of 2025 remains reasonable given clinical, manufacturing and general corporate spending.
- Review the complete Phase 1b LTI-03 dataset, including Cohort 2 results, statistical methodology, durability and safety findings.
- Monitor remediation of the material weaknesses and any effect on the reliability or timing of future SEC filings.
- Evaluate potential dilution from 12.653 million preferred-stock conversion shares, 3.727 million warrant shares and 2.127 million option shares outstanding or reserved at March 31, 2024, in addition to the May offering securities.